探究聚乙二醇多柔比星脂质体联合双靶向药物治疗人表皮生长因子受体2阳性早期乳腺癌的临床效果  

Exploring the Clinical Effect of Polyethylene Glycol Doxorubicin Lipo⁃somes Combined with Dual-targeted Drugs in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer

作　　者：刘慧敏 刘婧依 张俊红 LIU Huimin;LIU Jingyi;ZHANG Junhong(Chifeng Cancer Hospital,Chifeng 024000,Inner Mongolia Autonomous Region,China)

机构地区：[1]赤峰市肿瘤医院,内蒙古赤峰024000

出　　处：《系统医学》2025年第7期18-21,共4页Systems Medicine

摘　　要：目的 探讨双靶向药物与聚乙二醇多柔比星(polyethylene glycol doxorubicin, PLD)脂质体的联合疗法在人表皮生长因子受体2(human epidermal growth factor receptor 2, HER2)阳性早期乳腺癌患者治疗中的临床效果。方法 回顾性选取2021年2月—2024年2月赤峰市肿瘤医院收治的150例HER2阳性早期乳腺癌患者的临床资料。根据治疗方法分为对比组和观察组,对比组加用表柔比星治疗(n=75),观察组则额外采用PLD治疗(n=75)。对比两组肿瘤标志物水平、免疫功能、治疗有效率、不良反应发生情况。结果 治疗后,观察组肿瘤标志物水平低于对比组,观察组免疫功能优于对比组,差异均有统计学意义(P均<0.05)。治疗后,观察组客观缓解率为69.33%(52/75),疾病控制率为85.33%(64/75),高于对比组的30.67%(23/75)、61.33%(46/75),差异均有统计学意义(χ^(2)=9.801,5.477;P均<0.05)。观察组治疗后的过敏反应发生率较对比组高,脱发发生率较对比组更低,差异均有统计学意义(P均<0.05)。结论 相较于传统的表柔比星联合双靶向药物治疗方案,PLD联合双靶向药物治疗在降低HER2阳性早期乳腺癌患者的肿瘤标志物水平方面更为有效,并能显著提升患者的免疫功能,此外还展现出更高的总缓解率和疾病控制率,同时降低了脱发风险,整体疗效显著。Objective To investigate the clinical effect of combined therapy of dual-targeted drugs and polyethylene glycol doxorubicin(PLD)liposomes in the treatment of patients with human epidermal growth factor receptor 2(HER2)positive early breast cancer.Methods A retrospective selection was made of the clinical data from 150 pa⁃tients with HER2-positive early breast cancer who were admitted to Chifeng Cancer Hospital between February 2021 and February 2024.The study was divided into a control group and an observation group based on the treatment meth⁃ods.The control group received additional epirubicin treatment(n=75),while the observation group was additionally treated with PLD(n=75).The levels of tumor markers,immune function,treatment efficiency and adverse reactions were compared between the two groups.Results After treatment,the observation group showed lower tumor marker levels and better immune function compared to the control group,the differences were statistically significant(all P<0.05).After treatment,the objective remission rate of the observation group was 69.33%(52/75),and the disease con⁃trol rate was 85.33%(64/75),which were higher than 30.67%(23/75)and 61.33%(46/75)of the control group,and the differences were statistically significant(χ^(2)=9.801,5.477;both P<0.05).Compared to the control group,the obser⁃vation group showed a higher incidence of allergic reactions but a lower incidence of alopecia after treatment,the dif⁃ferences were statistically significant(both P<0.05).Conclusion Compared with the traditional epirubicin combined with dual-targeted drug therapy,PLD combined with dual-targeted drug therapy is more effective in reducing the level of tumor markers in patients with HER2-positive early breast cancer,and can significantly improve the immune function of patients.In addition,it also shows higher total remission rate and disease control rate,while reducing the risk of hair loss,and the overall efficacy is significant.

关 键 词：聚乙二醇多柔比星脂质体 双靶向药物 HER2 临床效果 

分 类 号：R737[医药卫生—肿瘤]